Diagnostic improvement in MRI of gynecological neoplasms.
The use of pelvic MRI is still limited because of motion artifacts due to respiration, blood flow and peristalsis and because of lack of contrast between bowel loops and adjacent organs. As in CT it has been suggested that the administration of an oral contrast agent might improve MR image quality. Both positive (T1) and negative (T2) agents have already been used in clinical trials. Lumirem (AMI-121) is a negative oral contrast agent consisting of a solution of superparamagnetic iron oxide particles with silicone coating. In a phase III clinical trial we have determined the safety and efficacy of Lumirem in the assessment of gynecological neoplasms. Twenty (20) patients underwent MRI at 1.5 Tesla. T1w SE and T2w fast SE images were obtained before and after the ingestion of 600-900 ml Lumirem.
Marincek
B
B
Department of Medical Radiology, Zurich, University Hospital, Switzerland.
D005260:Female; D052203:Ferrosoferric Oxide; D005833:Genital Neoplasms, Female / Q000175:diagnosis*; D006801:Humans; D007089:Image Enhancement; D007501:Iron / Q000009:adverse effects; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D010087:Oxides / Q000009:adverse effects; D010386:Pelvic Neoplasms / Q000175:diagnosis; D012833:Siloxanes / Q000009:adverse effects
D058185:Magnetite Nanoparticles; D010087:Oxides; D012833:Siloxanes; C088769:ferumoxsil; D007501:Iron; D052203:Ferrosoferric Oxide